Kiniksa Pharma Files 8-K on Operations & Financial Condition

Ticker: KNSA · Form: 8-K · Filed: 2024-01-04T00:00:00.000Z

Sentiment: neutral

Topics: financial-condition, regulation-fd, corporate-update

TL;DR

**Kiniksa just dropped an 8-K with fresh financial deets, so check their numbers.**

AI Summary

Kiniksa Pharmaceuticals, Ltd. filed an 8-K on January 4, 2024, to report on its results of operations and financial condition, as well as to make a Regulation FD disclosure. This filing indicates that the company is providing updated financial information, which is crucial for investors to understand its current performance and future prospects. For shareholders, this matters because it offers transparency into the company's financial health, potentially influencing stock valuation and investment decisions.

Why It Matters

This filing provides investors with current financial information, which is essential for evaluating Kiniksa Pharmaceuticals' performance and making informed investment decisions.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of financial information and does not inherently present new risks, but rather provides data for risk assessment.

Analyst Insight

A smart investor would review the full details of the 'Results of Operations and Financial Condition' and 'Regulation FD Disclosure' once available to understand the specific financial updates and their potential impact on Kiniksa Pharmaceuticals, Ltd.'s valuation.

Key Players & Entities

FAQ

What is the purpose of Kiniksa Pharmaceuticals, Ltd.'s 8-K filing on January 4, 2024?

The 8-K filing by Kiniksa Pharmaceuticals, Ltd. on January 4, 2024, is to report on its 'Results of Operations and Financial Condition' and to make a 'Regulation FD Disclosure'.

What is the exact name and jurisdiction of incorporation for the registrant?

The exact name of the registrant is Kiniksa Pharmaceuticals, Ltd., and its jurisdiction of incorporation is Bermuda.

What is the business address of Kiniksa Pharmaceuticals, Ltd. in Bermuda?

The business address for Kiniksa Pharmaceuticals, Ltd. in Bermuda is Clarendon House, 2 Church Street, Hamilton HM11, Bermuda.

What is the SEC file number associated with Kiniksa Pharmaceuticals, Ltd.?

The SEC file number for Kiniksa Pharmaceuticals, Ltd. is 001-38492.

What is the earliest event reported date in this 8-K filing?

The date of the earliest event reported in this 8-K filing is January 4, 2024.

Filing Stats: 720 words · 3 min read · ~2 pages · Grade level 10.7 · Accepted 2024-01-04 07:37:35

Key Financial Figures

Filing Documents

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On January 4, 2024, Kiniksa Pharmaceuticals, Ltd. (the "Company") issued a press release (the "Press Release") announcing, among other things, that (i) its preliminary year-end 2023 cash, cash equivalents and short-term investments of $206.3 million (unaudited) are expected to fund its current operating plan into at least 2027 and (ii) ARCALYST net revenue was $71.2 million and $233.1 million for the fourth quarter and full year 2023, respectively (unaudited). The preliminary selected financial results reported by the Company are unaudited, subject to adjustment, and provided as an approximation in advance of the Company's expected announcement of complete financial results in February 2024.

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. In addition to the information contained in Item 2.02, the Press Release also announced top-line data from Cohorts 1, 2 and 3 of the Company's Phase 2 clinical trial of abiprubart (KPL-404) in rheumatoid arthritis. In connection with such announcement, the Company posted an investor presentation (the "Investor Presentation") containing data from the trial to its website at investors.kiniksa.com. A copy of the Press Release and the Investor Presentation are furnished with this Current Report on Form 8-K as Exhibit 99.1 and Exhibit 99.2, respectively. The information contained in these Items 2.02 and 7.01 of this Current Report on Form 8-K and Exhibits 99.1 and 99.2 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing and except as expressly provided by specific reference in such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by Kiniksa Pharmaceuticals, Ltd., dated January 4, 2024 99.2 Kiniksa Pharmaceuticals, Ltd. Investor Presentation 104 Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KINIKSA PHARMACEUTICALS, LTD. Date: January 4, 2024 By: /s/ Madelyn Zeylikman Madelyn Zeylikman Senior Vice President, General Counsel and Secretary

View on Read The Filing